肌层浸润性膀胱癌新辅助免疫治疗的理论依据与结局
本文系统综述了免疫检查点阻断用于肌层浸润性膀胱癌根治性膀胱切除术前新辅助治疗的依据与临床结局。II期试验显示单药新辅助免疫检查点阻断的病理完全缓解率(CR)为31%至37%,联合化疗方案为33%至50%,且未延迟计划手术。长期生存数据有限,III期试验正在进行。
要点
- 单药新辅助免疫检查点阻断病理CR率31%至37%,联合化疗33%至50%。
- 新辅助免疫检查点阻断未延迟根治性膀胱切除术,耐受性良好。
- 长期生存获益未知,III期试验正在评估该策略。
核心结论
- 新辅助免疫检查点阻断对局部肌层浸润性膀胱癌显示出有效抗肿瘤疗效,但长期生存数据有限。
研究设计与样本
- 系统综述MEDLINE数据库2008年1月至2020年2月文献,并纳入近期会议公开摘要。
主要发现
- II期试验中单药新辅助免疫检查点阻断的病理完全缓解率(CR)为31%(抗PD-L1单抗阿替利珠单抗,n=27/88)至37%(抗PD-1单抗帕博利珠单抗,n=42/114)。
- 92%(n=87/95)和98%(n=112/114)的患者接受了根治性膀胱切除术。
- 新辅助免疫检查点阻断未延迟计划手术,检查点抑制剂单药治疗耐受性良好,术前未出现意外毒性。
- 早期I/II期试验中联合化疗与免疫检查点阻断显示增强的抗肿瘤疗效,病理CR范围为33%至50%。
临床怎么用
- 新辅助免疫检查点阻断可作为肌层浸润性膀胱癌根治性膀胱切除术前的一种有前景的治疗策略,但需等待III期试验结果明确其相对于含顺铂化疗方案的潜在优势。
局限性
- 长期生存数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune therapy has emerged as a powerful treatment of metastatic urothelial carcinoma. Over 20 ongoing studies are exploring this strategy in the neoadjuvant setting in patients with localized muscle-invasive bladder cancer. OBJECTIVE: To summarize the rationale and the clinical outcomes regarding the use of immune checkpoint blockade in the neoadjuvant setting before radical cystectomy. EVIDENCE ACQUISITION: A systematic review of the literature in the MEDLINE database was performed. The central search strategy used the terms bladder cancer, urothelial carcinoma, mice, human, immunotherapy, neoadjuvant therapy, atezolizumab, pembrolizumab, durvalumab, nivolumab, avelumab, ipilimumab, and tremelimumab. The search was limited to publications between January 2008 and February 2020. Publicly available relevant abstracts from recent meetings were also included. EVIDENCE SYNTHESIS: Phase II trials investigating neoadjuvant immune checkpoint blockade as a single agent before radical cystectomy reported a rate of pathological complete response (CR), ranging from 31% with an anti-PD-L1 monoclonal antibody (mAb) atezolizumab (n = 27/88) to 37% with anti-PD-1 mAb pembrolizumab (n = 42/114). Overall, 92% (n = 87/95) and 98% (n = 112/114) of the patients underwent radical cystectomy. Neoadjuvant immune checkpoint blockade did not delay planned surgery. Checkpoint inhibitor monotherapy was well tolerated, with no unexpected toxicity in the presurgical setting. Early phase I/II trials investigating neoadjuvant combination chemotherapy strategies with immune checkpoint blockers reported enhanced antitumor efficacy, with a pathological CR ranging from 33% to 50%. CONCLUSIONS: Although limited clinical data are available on long-term survival, neoadjuvant immune checkpoint blockade demonstrated effective antitumor efficacy for localized muscle-invasive bladder cancer. Phase III trials are currently investigating this strategy in the presurgical setting. PATIENT SUMMARY: Immunotherapy prior to surgery has been evaluated for patients with muscle-invasive bladder cancer. Although long-term survival benefit is unknown, such treatment strategy revealed a promising antitumor response rate for patients who underwent radical cystectomy. Ongoing prospective clinical trials will define the potential advantage of this approach over current cisplatin-based chemotherapeutic regimens alone or in combination.
引用
- Rouanne M, Bajorin DF, Hannan R, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol. 2020. PMID: 33177001. doi:10.1016/j.euo.2020.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。